Metraipolis › archive › dc_5ca6140af8e5

Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? — Europe PMC PMID:42142195

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42142195
DOI
10.1007/s11060-[numero omesso]-4
License (as archived)
solo-consultazione
Archived
2026-11-02T05:36:19.580Z
SHA-256 of the archived text
ce25892e21e62245e1d96c3e564e6507c112d28a9e9fdaa17dba0dd9eb7f4ff3
Stable URL of this page
https://metraipolis.com/documento/dc_5ca6140af8e5

How to cite

Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? — Europe PMC PMID:42142195 — Europe PMC (en), https://europepmc.org/article/MED/42142195 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5ca6140af8e5 (Metraipolis archive dc_5ca6140af8e5, sha256 ce25892e21e62245e1d96c3e564e6507c112d28a9e9fdaa17dba0dd9eb7f4ff3)
BibTeX
@misc{dc5ca6140af8e5,
  title = {Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? — Europe PMC PMID:42142195},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42142195},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5ca6140af8e5; sha256 ce25892e21e62245e1d96c3e564e6507c112d28a9e9fdaa17dba0dd9eb7f4ff3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42142195. Agents can read the archived copy with the MCP tool read_document.